17 Biotechnology Stocks with More Than 50% Upside

12. Centessa Pharmaceuticals (NASDAQ:CNTA)

Number of Hedge Fund Holders: 40

Upside Potential: 68.3%

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the 17 biotechnology stocks with more than 50% upside.

On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock. Her rating came after Truist Financial updated its projections following a thorough reassessment of the current data regarding the orexin-2 receptor agonist class.

On January 16, Biren Amin from Piper Sandler maintained an Overweight rating on Centessa Pharmaceuticals (NASDAQ:CNTA). He forecasted a $38 price target for the stock, which implied a 57% upside potential.

Amin highlighted two major catalysts expected this quarter. These include the planned initiation of Phase 3 trials for ORX750 across NT1, NT2, and IH, along with additional findings from the CRYSTAL-1 Phase 2 study. The analyst is optimistic about idiopathic hypersomnia as it may represent a larger and potentially underappreciated market opportunity.

Centessa Pharmaceuticals (NASDAQ:CNTA) is involved in the discovery and development of transformative medicines for neurological and neurodegenerative diseases. The company operates under an asset-centric Research and Development model, with a portfolio of subsidiaries that support specialized research programs. These individual programs are treated as separate entities to ensure highly efficient, data-driven decision-making.